Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boehringer Ingelheim Pharmaceuticals has launched Spiriva Respimat (tiotropium bromide) Inhalation Spray in retail pharmacies across the US and will be available by prescription.
Subscribe to our email newsletter
Recently, Spiriva Respimat was approved by the US Food and Drug Administration (FDA) for the long-term, once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD) as well as to reduce COPD exacerbations.
The drug was developed to deliver medication through a slow-moving mist that helps patients inhale the medication.
Boehringer Ingelheim Pharmaceuticals vice-president of Clinical Development & Medical Affairs Danny McBryan said: "For 10 years, Spiriva HandiHaler has been a trusted maintenance therapy for patients with COPD, and Boehringer Ingelheim is proud to now offer another inhaler choice, Spiriva Respimat.
"Spiriva Respimat represents Boehringer Ingelheim’s continuing commitment to the COPD community to provide new treatment options."
The company said that Spiriva Respimat delivers medication independent of inspiratory effort.
As with all inhaled drugs, the actual amount of drug delivered to the lung will depend on patient factors, such as coordination between actuation of the inhaler and inspiration through the delivery system.